出 处:《四川生理科学杂志》2024年第12期2665-2667,2731,共4页
摘 要:目的:探讨便秘型肠易激综合征联合应用枸橼酸莫沙必利与双歧杆菌四联活菌治疗的疗效及安全性。方法:选取2021年1月至2023年12月期间本院消化内科收治的79例便秘型肠易激综合征患者,随机分为对照组(n=40)和研究组(n=39)。对照组口服枸橼酸莫沙必利片5 mg·次^(-1),3次·d^(-1)治疗,研究组在此基础上联合口服双歧杆菌四联活菌1.5 g·次^(-1),3次·d^(-1)治疗。治疗1m后参照疗效评价标准比较两组临床疗效,治疗前、治疗1 m后采用干化学法测定D-乳酸(D-lactic acid,D-LA)、内毒素(Endotoxin,ET),采用动态浊度法测定二胺氧化酶(Diamine oxidase,DAO),通过菌落群培养检测双歧杆菌、乳酸杆菌、肠杆菌,并观察用药期间不良反应发生情况。结果:研究组的临床疗效显著高于对照组(P<0.05)。治疗后,两组的双歧杆菌、乳酸杆菌均比治疗前显著升高,肠杆菌比治疗前显著降低,且研究组的双歧杆菌、乳酸杆菌显著高于对照组,肠杆菌显著低于对照组(P<0.05)。治疗后,两组的D-LA、ET、DAO均比治疗前显著降低,且研究组的D-LA、ET、DAO均显著低于对照组(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论:枸橼酸莫沙必利联合双歧杆菌四联活菌治疗便秘型肠易激综合征可提高疗效,改善肠道菌群及肠粘膜屏障功能。Objective:To investigate the efficacy and safety of the combination of mosapride citrate and bifidobacterium quadruple viable bacteria in treating irritable bowel syndrome.Method:A total of 79 patients with irritable bowel syndrome admitted to the Department of Gastroenterology of our hospital from January 2021 to December 2023 were randomly divided into a control group(n=40)and a study group(n=39).The control group was treated with oral administration of mosapride citrate tablets 5 mg,3 times•day^(-1),and the study group was treated with oral administration of bifidobacterium quadruple viable bacteria 1.5 g,3 times•day^(-1)on this basis.After 1 month of treatment,the clinical efficacy of the two groups was compared according to the efficacy evaluation criteria.Before and after treatment,D-lactic acid(D-LA)and endotoxin(ET)were measured by the dry chemistry method,and diamine oxidase(DAO)was measured by the dynamic turbidity method.Bifidobacteria,lactobacilli,and enterobacteria were detected by colony culture,and adverse reactions during the medication period were observed.Results:The clinical efficacy of the study group was significantly higher than that of the control group(P<0.05).After treatment,the levels of bifidobacteria and lactobacilli in both groups significantly increased compared with those before treatment,while the levels of enterobacteria significantly decreased compared with those before treatment.The levels of bifidobacteria and lactobacilli in the study group were significantly higher than those in the control group,and the levels of enterobacteria were lower than those in the control group(P<0.05).After treatment,the D-LA,ET,and DAO levels in both groups were lower than those before treatment,and the D-LA,ET,and DAO levels in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined use of mosapride citrate and bifidobacterium quadruple can
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...